Akebia Therapeutics traded at $0.40 this Friday July 1st, increasing $0.04 or 11.98 percent since the previous trading session. Looking back, over the last four weeks, Akebia Therapeutics gained 9.99 percent. Over the last 12 months, its price fell by 89.34 percent. Looking ahead, we forecast Akebia Therapeutics to be priced at 0.36 by the end of this quarter and at 0.33 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.40
Daily Change
11.98%
Yearly
-89.34%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 2,058.50 -56.50 -2.67% 6.99%
Acadia Pharmaceuticals 14.48 0.39 2.77% -40.41%
Agios Pharmaceuticals 23.27 1.10 4.96% -58.25%
Akebia Therapeutics 0.40 0.04 11.98% -89.34%
Alnylam Pharmaceuticals 147.69 1.84 1.26% -13.85%
Amgen 244.96 1.66 0.68% -1.50%
Ardelyx 0.60 0.01 1.63% -92.40%
Avrobio Inc 0.93 0.01 1.62% -89.54%
AstraZeneca 10,754.00 -46.00 -0.43% 22.50%
Bayer 57.35 0.63 1.11% 11.42%
BioMarin Pharmaceutical 84.33 1.46 1.76% -1.34%
Exelixis 21.29 0.47 2.26% 16.59%
Fresenius Medical Care 47.58 -0.05 -0.11% -31.08%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Intercept Pharmaceuticals 13.75 -0.06 -0.43% -31.22%
Ionis Pharmaceuticals 37.80 0.78 2.10% -5.31%
Ironwood Pharmaceuticals 11.41 -0.12 -1.04% -9.30%
J&J 178.69 1.18 0.66% 5.75%
Karyopharm Therapeutics 4.60 0.09 1.88% -56.28%
Lexicon Pharmaceuticals 1.91 0.05 2.42% -53.76%
Moderna Inc 149.52 6.67 4.67% -36.18%
Nektar Therapeutics 3.74 -0.07 -1.71% -78.17%
Opko Health 2.63 0.10 3.95% -34.41%
Prothena 27.97 0.82 3.02% -49.58%
PTC Therapeutics 41.19 1.13 2.82% -4.41%
Regeneron Pharmaceuticals 594.86 3.73 0.63% 1.92%
Roche Holding 320.40 1.85 0.58% -8.34%
Sanofi 97.52 1.18 1.22% 10.94%
Seattle Genetics 178.79 1.85 1.05% 13.68%
Sarepta Therapeutics 75.05 0.09 0.12% -0.25%
Vanda Pharmaceuticals 11.09 0.19 1.74% -46.73%

Indexes Price Day Year
USND 11088 59.18 0.54% -24.26%
US2000 1722 14.25 0.83% -25.31%

Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in dialysis-dependent (DD)-CKD adult patients and the treatment of iron deficiency anemia (IDA), in non-dialysis dependent (NDD)-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.